Related Experiment Video
Updated: Jan 16, 2026
An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy
Published on: January 25, 2019
The Incidence of Post-Operative Fibrinoid Syndrome in Diabetic Eyes Receiving a Dexamethasone Implant During Pars
Reem ElSheikh1, Sairi Zhang1, Mohammad Z Siddiqui1
1Department of Ophthalmology, Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Introduction:
The dexamethasone implant (DEX) and pars plana vitrectomy (PPV) are both used to treat diabetic retinopathy. A rare complication of vitrectomy is post-operative fibrinoid syndrome (POFS). We report the incidence of POFS when PPV is combined with DEX injection in diabetic eyes.
Methods:
One hundred and five eyes of patients with diabetic retinopathy undergoing concurrent PPV and DEX were retrospectively analyzed.
Results:
Mean BCVA improved from 1.06 logMAR to 0.78 (p=0.05) at final follow-up. Mean CST was found to have a statistically insignificant decrease from 360 ± 154 µm to 314 ± 99 µm at final visit (p=0.13). Four eyes (3.8%) developed POFS. No major surgical complications were encountered.
Conclusion:
Combining PPV with DEX is safe and effective in patients with diabetic retinopathy. Our results showed an improvement in mean BCVA and a decrease in CST. The incidence of POFS was 3.8%, which is not significantly different from previously published data in 1982.
